newsfilter
← Latest News
ACCESS Newswire·

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Publication of an inside information according to Article 17 para. 1 of the Regulation No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate The key secondary endpoints